Pharmos Begins Dosing in New Phase IIa Pain Study
Posted on: Friday, 11 August 2006, 12:00 CDT
Pharmos Corporation, which recently entered into a definitive agreement to acquire Vela Pharmaceuticals, has posted news about its cannabinoid drug candidate, cannabinor, revealing that dosing has commenced in a second phase IIa clinical study for the treatment of pain.
The proof-of-concept trial will test for analgesic activity and the safety of cannabinor (PRS-211,375), a CB2-selective synthetic cannabinoid drug candidate, in healthy subjects experiencing capsaicin-induced pain.
In this phase IIa experimentally induced pain trial, cannabinor will be tested intravenously in a single-center, randomized, double-blinded study that will take place at the UCL Analgesia Centre in London. The safety and analgesic efficacy of cannabinor will be compared with placebo on capsaicin evoked allodynia (pain resulting from a non-noxious stimulus to the skin) and hyperalgesia (abnormally increased pain sense).
The study will include 24 male subjects in a two-way crossover design and is expected to be completed in the fourth quarter of 2006.
The company has also announced that patient enrollment is continuining in its separate phase IIa clinical trial of cannabinor as a treatment for nociceptive pain in third molar dental extraction. This trial is expected to be completed in the third quarter of 2006.
In addition to the ongoing clinical testing of cannabinor in an intravenous formulation, Pharmos is also developing an oral formulation of the drug candidate to move into phase I testing in late 2006 or early 2007.
Source: Datamonitor
Related Articles
- PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis
- Archemix Announces Initiation of Phase 2 Trial for Aptamer Product Candidate ARC1779 in Patients With TTP, a Rare, Life-Threatening Blood Disorder
- Targacept to Receive $6 Million From GlaxoSmithKline for Initiation of Phase I Trial of Neuropathic Pain Candidate
- FDA Asks Neopharm for Phase 3 Trial
- La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
- ProEthic Pharmaceuticals Announces Positive Phase I Trial Results for Fast-Acting Acute Pain Product Candidate; Trials Confirm Strong Pharmacokinetic Profile of PRO-571
- GTx, Inc. Initiates Phase II Clinical Trial of Ostarine, a First-in-Class Drug
- Preliminary Data From CAIV-T Pivotal Phase 3 Trial Demonstrate Clinical Efficacy Over Flu Shot in Head-to-Head Influenza Study
- Pharmos Initiates Phase I Trial of CB2-Selective Drug Candidate Cannabinor
- Telik Announces Positive Data From Phase 2 Trial Of TELINTRA In Myelodysplastic Syndrome
 |
 |
User Comments (0)
RSS Feeds